Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096321 | 0.85 | POLB (0.47) | POLBCASP6SLC6A4SLC6A3BRD4 | |
| SCHEMBL3090293 | 0.80 | CNR1 (0.48) | POLBCASP6HSD17B14PTGER3KMT2A | |
| SCHEMBL3088897 | 0.80 | POLB (0.52) | POLBCASP6SLC6A3BRD4SLC6A2 | |
| SCHEMBL5478134 | 0.79 | POLB (0.41) | POLBCASP6BRD4KMT2A | |
| SCHEMBL31184813 | 0.78 | POLB (0.40) | POLBCASP6BRD4KMT2A | |
| SCHEMBL3085279 | 0.77 | BRD4 (0.41) | POLBCASP6ALDH1A1BRD4KMT2A | |
| SCHEMBL31185005 | 0.77 | POLB (0.41) | POLBCASP6BRD4 | |
| SCHEMBL3093541 | 0.76 | MMP13 (0.47) | POLBCASP6SLC6A3SLC6A2 | |
| SCHEMBL31003710 | 0.75 | SLC6A4 (0.40) | POLBCASP6SLC6A4SLC6A3 | |
| SCHEMBL3096028 | 0.75 | POLB (0.37) | POLBCASP6BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TOPOTARGET A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| WO-2008129075-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS | TOPOTARGET A/S (DK) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227863-A1 | SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS | TPH2, TPH1, HTR2C | POLB 2212/4885CASP6 2159/4885ALDH1A1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.